Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00192335 · ClinicalTrials.gov registry record · Phase 3
Trial to Demonstrate Equivalent Immunogenicity of CAIV-T and FLUMIST in Healthy Participants
A Phase 3 study of Healthy, sponsored by MedImmune.
- Completed
- Registry status
- Phase 3
- Development phase
- 890
- Enrollment target
- 3
- Study locations
NCT00192335: Completed Phase 3 study of Healthy, sponsored by MedImmune.
NCT00192335 is a Phase 3 study of Healthy that has completed, run by MedImmune. The registered enrollment target is 890 participants, above the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (38% higher). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00192335, a Phase 3 study of Healthy, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 890 participants
- Enrollment target
- 3
- Study locations
Study Summary
* Primary objective is to demonstrate equivalent immunogeniticity of CAIV-T and FluMist * Secondary objective of this study is to assess the safety and tolerability of CAIV-T compared to FluMist
Conditions Studied
Interventions
- BIOLOGICAL FluMist
- BIOLOGICAL CAIV-T
- BIOLOGICAL CAIVT
Study Locations (3)
Kansas
- Heart of America Research Institute - Shawnee Mission
Kentucky
- Kentucky Pediatric/Adult Research, Inc. - Bardstown
Texas
- R/D Clinical Research, Inc. - Lake Jackson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 890 participants |
| Start Date | 2004-07 |
| Est. Completion | 2005-02 |
| Phase | Phase 3 |
What the finished NCT00192335 record still lists
NCT00192335 is an interventional study that assigns participants to a tested intervention. The registered 890 participants enrollment target is mid-sized for trials with a published cap, above the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (38% higher).
The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 3 interventions - of which FluMist is the first listed.
NCT00192335 reports a single indexed study location in Kansas, Kentucky, Texas.
Frequently Asked Questions
What is clinical trial NCT00192335 about?
NCT00192335 is a clinical study titled "Trial to Demonstrate Equivalent Immunogenicity of CAIV-T and FLUMIST in Healthy Participants". * Primary objective is to demonstrate equivalent immunogeniticity of CAIV-T and FluMist * Secondary objective of this study is to assess the safety and tolerability of CAIV-T compared to FluMist
What is the current status of trial NCT00192335?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 890 participants. The study started on 2004-07. Estimated completion is 2005-02.
What conditions does trial NCT00192335 study?
This clinical trial studies the following conditions: Healthy.
What interventions are being tested in trial NCT00192335?
The interventions under investigation include: FluMist (BIOLOGICAL), CAIV-T (BIOLOGICAL), CAIVT (BIOLOGICAL).
Who is sponsoring clinical trial NCT00192335?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00192335 being conducted?
This trial has 3 study locations across Kansas, Kentucky, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00192335's enrollment target sits among peer trials
890 33rd of 1090 higher than 1,058 of 1,090 other Healthy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies
RECRUITING · Phase 3
-
Filgrastim-Mobilized Stem Cells for Transplantation Using Unrelated Donors
RECRUITING · Phase 3
-
Long-term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101
COMPLETED · Phase 3
-
A Study to Evaluate the Effect of Genetic Variation on Beta-cell Function During Fasting and Hyperglycemia in Nondiabetics
COMPLETED · Phase 3
-
Study to Investigate the Potential of Probiotics in Yogurt
COMPLETED · Phase 3
-
Study to Evaluate the Safety of a Bivalent Vaccine of New 6:2 Influenza Virus Reassortants in Healthy Adults
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03564340 · 890 participants · Phase 1
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
- NCT05855200 · 892 participants · Phase 3
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
- NCT04862663 · 895 participants · Phase 3
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
- NCT07196748 · 882 participants · Phase 3
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia